Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1 Mln
P/E Ratio
--
P/B Ratio
0.74
Industry P/E
--
Debt to Equity
0.04
ROE
-3.55 %
ROCE
-343.01 %
Div. Yield
0 %
Book Value
0.57
EPS
-3.95
CFO
$-40.47 Mln
EBITDA
$-51.10 Mln
Net Profit
$-110.50 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Processa Pharmaceuticals (PCSA)
| -74.04 | -41.03 | -61.05 | -89.33 | -84.06 | -72.65 | -56.66 |
|
BSE Sensex*
| 2.83 | 3.94 | 4.82 | 7.75 | 12.14 | 19.72 | 11.45 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Processa Pharmaceuticals (PCSA)
| -86.59 | -69.55 | -77.55 | -25.70 | -63.36 | -28.57 | -18.09 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.42 | 6,839.20 | -- | 38.11 | |
| 73.23 | 7,493.81 | 57.68 | 23.56 | |
| 60.43 | 11,518.55 | 396.8 | 0.76 | |
| 8.34 | 9,847.94 | -- | -3.24 |
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an... alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine, which is in Phase 2 clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 that is in Phase 2B clinical trials for treatment of gastroparesis; and PCS499 for the treatment of glomerular disease. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2017 and is based in Hanover, Maryland. Address: 7380 Coca Cola Drive, Hanover, MD, United States, 21076 Read more
Chief Executive Officer
Mr. George K. Ng Esq., J.D.
Chief Executive Officer
Mr. George K. Ng Esq., J.D.
Headquarters
Hanover, MD
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Processa Pharmaceuticals Inc (PCSA) stood at $ 3 Mln as on 31-Dec-24
The share price of Processa Pharmaceuticals Inc (PCSA) is $0.23 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Processa Pharmaceuticals Inc (PCSA) has given a return of -84.06% in the last 3 years.
Processa Pharmaceuticals Inc (PCSA) has a market capitalisation of $ 1 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Processa Pharmaceuticals Inc (PCSA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Processa Pharmaceuticals Inc (PCSA) and enter the required number of quantities and click on buy to purchase the shares of Processa Pharmaceuticals Inc (PCSA).
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine, which is in Phase 2 clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 that is in Phase 2B clinical trials for treatment of gastroparesis; and PCS499 for the treatment of glomerular disease. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2017 and is based in Hanover, Maryland. Address: 7380 Coca Cola Drive, Hanover, MD, United States, 21076
The CEO & director of Mr. George K. Ng Esq., J.D.. is Processa Pharmaceuticals Inc (PCSA), and CFO & Sr. VP is Mr. George K. Ng Esq., J.D..
There is no promoter pledging in Processa Pharmaceuticals Inc (PCSA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
731
|
|
|
670
|
| Processa Pharmaceuticals Inc. (PCSA) | Ratios |
|---|---|
|
Return on equity(%)
|
-354.51
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Processa Pharmaceuticals Inc (PCSA) was $0 Mln.
$-0.01
(
